Comparing Aytu BioPharma (NASDAQ:AYTU) & Harrow (NASDAQ:HROW)

Harrow (NASDAQ:HROW) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Analyst Ratings

This is a summary of current recommendations for Harrow and Aytu BioPharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	9	0	2.67
Aytu BioPharma	1	1	2	0	2.25

Harrow presently has a consensus target price of $66.38, suggesting a potential upside of 94.02%. Aytu BioPharma has a consensus target price of $10.75, suggesting a potential upside of 445.69%. Given Aytu BioPharma’s higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Harrow.

Profitability

This table compares Harrow and Aytu BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Insider & Institutional Ownership

72.8% of Harrow shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Harrow and Aytu BioPharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	4.71	-$5.14 million	($1.00)	-34.21
Aytu BioPharma	$66.38 million	0.32	-$13.56 million	($4.58)	-0.43

Harrow has higher revenue and earnings than Aytu BioPharma. Harrow is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Harrow has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Harrow beats Aytu BioPharma on 11 of the 14 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About Aytu BioPharma

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.